OLD Point Trust & Financial Services N A Sells 1,400 Shares of Pfizer Inc. (NYSE:PFE)

OLD Point Trust & Financial Services N A lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 74,915 shares of the biopharmaceutical company’s stock after selling 1,400 shares during the quarter. OLD Point Trust & Financial Services N A’s holdings in Pfizer were worth $2,692,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Heritage Way Advisors LLC increased its position in Pfizer by 0.6% during the second quarter. Heritage Way Advisors LLC now owns 57,524 shares of the biopharmaceutical company’s stock worth $2,492,000 after acquiring an additional 354 shares during the period. Natixis bought a new stake in Pfizer in the 2nd quarter valued at $258,466,000. Machina Capital S.A.S. increased its holdings in Pfizer by 14.4% in the 2nd quarter. Machina Capital S.A.S. now owns 43,837 shares of the biopharmaceutical company’s stock valued at $1,899,000 after buying an additional 5,522 shares during the period. Integrated Wealth Concepts LLC increased its holdings in Pfizer by 14.2% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 68,060 shares of the biopharmaceutical company’s stock valued at $2,840,000 after buying an additional 8,445 shares during the period. Finally, Annex Advisory Services LLC increased its holdings in Pfizer by 0.7% in the 2nd quarter. Annex Advisory Services LLC now owns 51,785 shares of the biopharmaceutical company’s stock valued at $2,243,000 after buying an additional 382 shares during the period. 71.66% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts have issued reports on PFE shares. Bank of America started coverage on shares of Pfizer in a report on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 price target on the stock. Morgan Stanley lowered their price target on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 27th. JPMorgan Chase & Co. boosted their price target on shares of Pfizer from $37.00 to $46.00 and gave the company a “neutral” rating in a report on Thursday, September 19th. They noted that the move was a valuation call. ValuEngine raised shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, UBS Group reissued a “neutral” rating and issued a $43.00 price target on shares of Pfizer in a report on Monday, August 5th. Eleven equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Pfizer has an average rating of “Hold” and a consensus price target of $44.47.

Shares of PFE traded up $0.46 during trading hours on Monday, hitting $37.23. The stock had a trading volume of 1,297,683 shares, compared to its average volume of 15,217,859. The company’s fifty day moving average is $36.32 and its two-hundred day moving average is $39.51. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.47 and a quick ratio of 1.21. Pfizer Inc. has a 52 week low of $33.97 and a 52 week high of $46.47. The stock has a market capitalization of $201.27 billion, a price-to-earnings ratio of 12.42, a P/E/G ratio of 2.16 and a beta of 0.66.

Pfizer (NYSE:PFE) last posted its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.05. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The business had revenue of $13.26 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the firm earned $0.77 EPS. The firm’s quarterly revenue was down 1.5% compared to the same quarter last year. Equities analysts predict that Pfizer Inc. will post 2.81 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.36 dividend. This represents a $1.44 annualized dividend and a dividend yield of 3.87%. The ex-dividend date is Thursday, November 7th. Pfizer’s payout ratio is 48.00%.

In related news, major shareholder Pfizer Inc purchased 50,000 shares of Pfizer stock in a transaction that occurred on Tuesday, September 17th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $900,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Scott Gottlieb purchased 3,000 shares of Pfizer stock in a transaction that occurred on Friday, August 23rd. The shares were bought at an average price of $34.72 per share, for a total transaction of $104,160.00. Following the transaction, the director now owns 3,000 shares in the company, valued at $104,160. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by corporate insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: Initial Coin Offering (ICO)

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.